Exelixis, Inc.
Exelixis, Inc., a prominent biotechnology firm headquartered in the United States, has established itself as a leader in the oncology sector since its founding in 1994. With a focus on developing innovative cancer therapies, Exelixis operates primarily in North America and has made significant strides in advancing targeted treatments for various malignancies. The company’s flagship product, cabozantinib, exemplifies its commitment to precision medicine, offering unique mechanisms of action that address complex tumour biology. Exelixis has achieved notable milestones, including successful clinical trials and strategic partnerships, solidifying its position in the competitive biopharmaceutical landscape. With a robust pipeline and a dedication to improving patient outcomes, Exelixis continues to be a key player in the fight against cancer.
DitchCarbon Score
How does Exelixis, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Exelixis, Inc.'s score of 18 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Exelixis, Inc.'s reported carbon emissions
Exelixis, Inc., headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor does it specify any reduction targets or initiatives related to climate commitments. Without specific emissions figures or defined goals, it is challenging to assess their environmental impact or progress in sustainability. The absence of data suggests that Exelixis may still be in the early stages of formalising its climate strategy or reporting practices. As the biopharmaceutical industry increasingly prioritises sustainability, it will be essential for Exelixis to establish clear emissions reduction targets and commitments to align with industry standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Exelixis, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
